Data from electronic health records aren’t always helpful for oncologists, which is why the founders of Cancer Outcomes Tracking and Analysis (COTA) developed a platform that stratifies patients by relevant characteristics, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.
Data from electronic health records aren’t always helpful for oncologists, which is why the founders of Cancer Outcomes Tracking and Analysis (COTA) developed a platform that stratifies patients by relevant characteristics, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.
Transcript (slightly modified)
What makes the COTA platform different from traditional data analysis programs?
Today most people use electronic health records, and they were really set up for billing purposes. They’re all based on IC-9 or IC-10, which are very broad characteristics that are helpful to the billing coders, but not insightful to the oncologist. So we’ve developed an entire system that’s based on stratifying the patients by the patient characteristics. It could be the size of the tumor, it could be genomics, it could be patient factors, like heart disease or diabetes.
We put all that into a digital code so that then we can do analytics. That’s very different than just boiling the ocean, looking for some type of insight to come out. As oncologists, when we founded COTA, we understood what we needed to look for, and we organized the patients around oncology-specific factors that every oncologist would understand readily.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More